QPPV.COM KNOWLEDGE ASSESSMENT

ICSR Management for Biological Medicinal Products

Test your understanding of the concepts covered by ICSR Management for Biological Medicinal Products.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should chronology for a biological ICSR include prior tolerated exposures and cumulative exposure, rather than only the interval between the last dose and event?

Because prior tolerance and re-exposure can inform, but do not alone determine, the assessment of causality Because the last dose is never relevant for biological medicines Because cumulative exposure automatically proves immunogenicity Because chronological information is required only for quality complaints

Question 2 of 10 Which item most directly links a biological exposure to manufacturing, release, and distribution records?

The patient's prescription number The batch or lot identifier The reporter's profession The expiry date alone

Question 3 of 10 A reporter states that a patient used a biologic injection but provides no brand, pack photograph, or dispensing record. What is the soundest product-identification practice?

Infer the brand from the country and indication Assign the brand of the most commonly used product in that market Record the supported product information and leave unsupported fields unknown while seeking evidence Use the marketing authorisation holder as the product name

Question 4 of 10 What is the most appropriate attribution when several reports involve administration failures with one presentation's injector, but no evidence indicates a medicinal-product manufacturing defect?

Batch-level medicinal-product defect Device or formulation-level contribution requiring investigation Active-substance class effect No safety-relevant issue because administration problems are never reportable

Question 5 of 10 A patient who previously responded to a biological develops worsening disease after an injection device failed to deliver the full dose. Which interpretation is most appropriate?

The event is necessarily secondary loss of response caused by anti-drug antibodies The event is necessarily a batch defect Incomplete delivery is a plausible administration or device contributor, but disease activity and other causes should still be assessed Loss of response cannot be reported when a device is involved

Question 6 of 10 Which statement correctly distinguishes seriousness from severity?

Seriousness and severity are interchangeable regulatory terms A severe event is always serious, while a mild event is never serious Seriousness concerns regulatory outcomes or consequences, whereas severity describes intensity Seriousness is determined only by the product's reference safety information

Question 7 of 10 A homecare provider receives a valid report three days before it is transferred to the marketing authorisation holder's central safety database. Which date generally controls the start of the regulatory reporting clock?

The date the central safety database creates the case The date the case is medically reviewed The date the covered organisation or partner first received the minimum information for a valid report The date the reporter confirms the batch number

Question 8 of 10 Which interpretation best describes biological plausibility in causality assessment?

It proves that the medicine caused the event It indicates consistency with known pharmacology, immunology, or product characteristics and supports, but does not establish, a causal hypothesis It replaces the need to consider alternative explanations It is determined solely by the presence of a batch number

Question 9 of 10 Which statement about a quality investigation conclusion is correct?

A finding of no defect invalidates the patient's reported clinical reaction A confirmed defect always proves the medicinal product caused the reaction A no-defect finding does not invalidate the clinical case, and a confirmed defect may require action even without a valid ICSR Quality findings are never relevant to causality or signal assessment

Question 10 of 10 What is the primary relationship between pharmacovigilance and quality investigations in a case involving a suspected device defect and an adverse reaction?

The quality investigation replaces the ICSR once a complaint is opened PV and quality answer identical questions and should use one shared record only PV assesses the clinical case and reporting obligations, while quality investigates product or device conformity; the processes should be linked and reconciled PV must wait for the quality conclusion before submitting the ICSR

ICSR Management for Biological Medicinal Products

Cookie Settings